OPKO Health and Entera Bio abstract selected for ESPEN Congress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
July 8, 2025 8:00 AM EDTMIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) and Entera Bio Ltd. (NASDAQ: ENTX) (Entera) today announced that their abstract First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress, taking place September 1316, 2025, in Prague, Czech Republic.
Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome
Poster Viewing Date & Time: September 13, 2025, 3:30 - 4:00 p.m. local time &... More
